Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 2011. The report details a specific share repurchase transaction executed on December 2, 2011, in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 400,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,420.5 pence per share; lowest price paid was 1,407 pence per share.
- Treasury Holdings (Settled): 529,082,927 shares (9.49% of total issued share capital).
- Treasury Holdings (Including Unsettled): 530,282,927 shares (10.50% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,047,921,353 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 400,000 shares. This transaction increased the Company's treasury holdings, raising the percentage of total voting rights held in treasury to 10.50% when including unsettled shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities. No specific risks or contingencies are detailed beyond standard regulatory disclosures regarding the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,047,921,353) for calculating disclosure thresholds under the Financial Services Authority's rules.
- Confirm the current percentage of voting rights held in Treasury (10.50% including unsettled shares).
- Review the price range paid (1,407 to 1,420.5 pence) to assess the cost of capital return relative to market prices at the time.